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 Statement of translational relevance 
 
Patients with leukemic cutaneous T cell lymphoma (L-CTCL) have an average 3-5 year 
survival, die most commonly from infection and have clinical abnormalities consistent 
with a Th2-driven immunologic process. We find both malignant and benign T cells in L-
CTCL are markedly Th2 biased, demonstrating a global Th2 skewing. Culture of benign 
T cells away from the malignant clone reduced Th2 and enhanced Th1 responses but 
separate culture had no effect on malignant T cells. Co-culture of healthy T cells with L-
CTCL T cells reduced IFNγ production and neutralizing antibodies to IL-4 and IL-13 
restored Th1 responses. In patients, enhanced Th1 responses were observed following 
a variety of treatment modalities that reduced malignant T cell burden suggesting that 
Th2 cytokines produced by malignant T cells play a critical role in down-regulating Th1 
responses in vivo. Results suggest that neutralization of Th2 cytokines may be beneficial 
in enhancing immune responses both to pathogens and to the malignancy itself. 
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Abstract 
Purpose: In leukemic CTCL (L-CTCL) malignant T cells accumulate in the blood and 
give rise to widespread skin inflammation. Patients have intense pruritus, increased IgE, 
decreased Th1 responses and most die from infection. Depleting malignant T cells while 
preserving normal immunity is a clinical challenge. L-CTCL has been variably described 
as a malignancy of regulatory, Th2 and Th17 cells.  
Experimental design: We analyzed phenotype and cytokine production in malignant 
and benign L-CTCL T cells, characterized the effects of malignant T cells on healthy T 
cells and studied the immunomodulatory effects of treatment modalities in L-CTCL 
patients.  
Results: 12/12 L-CTCL patients overproduced Th2 cytokines. Remaining benign T cells 
were also strongly Th2 biased, suggesting a global Th2 skewing of the T cell repertoire. 
Culture of benign T cells away from the malignant clone reduced Th2 and enhanced Th1 
responses but separate culture had no effect on malignant T cells. Co-culture of healthy 
T cells with L-CTCL T cells reduced IFNγ production and neutralizing antibodies to IL-4 
and IL-13 restored Th1 responses. In patients, enhanced Th1 responses were observed 
following a variety of treatment modalities that reduced malignant T cell burden.  
Conclusions: A global Th2 bias exists in both benign and malignant T cells in L-CTCL 
and may underlie the infectious susceptibility of patients.  Th2 cytokines from malignant 
cells strongly inhibited Th1 responses. Our results suggest therapies that inhibit Th2 
cytokine activity, by virtue of their ability to improve Th1 responses, may have the 
potential to enhance both anti-cancer and anti-pathogen responses. 
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Introduction 
 Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin’s 
lymphomas arising from malignant transformation of T cells that home to and populate 
the skin (1, 2). In leukemic variants of CTCL (L-CTCL), malignant T cells can accumulate 
in the blood and lymph nodes and also produce widespread inflammatory skin lesions. 
L-CTCL is often refractory to multiple therapies and patients often ultimately require 
hematopoietic stem cell transplantation (3). The median survival for patients with L-
CTCL varies with the extent of malignant T cell burden but is generally 2-5years and 
patients die most commonly from infection (4-7). 
 CTCL has been proposed to be a malignancy of three separate T cell populations: 
FOXP3+ Treg, Th2 T cells and Th17 T cells (8-10).  Clinically, patients with L-CTCL have 
abnormalities suggestive of a Th2 driven immunologic process, including decreased 
antigen specific T cell responses, impaired cell mediated cytotoxicity, peripheral 
eosinophilia, and elevated levels of serum IgE and IgA (11-13). Prior studies have 
shown increased levels of Th2 cytokines and Th2 associated genes in T cells from 
patients with L-CTCL (9, 14-17) but a recent report claims that malignant T cells in the 
disease are actually Th17 biased (10). 
 We performed comprehensive analyses of the cytokine production of benign and 
malignant T cells from L-CTCL with identifiable malignant T cell clones. We report here 
that both malignant and benign T cells in L-CTCL patients were strongly Th2 biased, that 
this bias was intrinsic in malignant T cells but extrinsic in benign cells and that inhibition 
of Th2 cytokines led to recovery of Th1 responses in benign T cells. 
 
Materials and Methods 
 
Comment [r1]: References 6 and 7 are new 
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Blood samples. The protocols of this study were performed in accordance with the 
Declaration of Helsinki and were approved by the Institutional Review Board of the 
Partners Human Research Committee (Partners Research Management, Boston, 
MA, USA). Blood from healthy individuals was obtained as discarded tissue following 
leukopheresis. Blood and lesional skin from patients with CTCL were obtained from 
patients seen at the Dana-Farber/Brigham and Women’s Cancer Center Cutaneous 
Lymphoma Program. L-CTCL patients described in this manuscript met the WHO-
EORTC criteria for L-CTCL/SS (18). Patient characteristics are included in Table I; 
based on the malignant T cell burden in this cohort of patients, expected survival is 
approximately 5 years (4-7). PBMC were isolated by ficoll centrifugation and clonal and 
non-clonal CD4+ T cells from CTCL patients were isolated using magnetic bead 
separation (Miltenyi Biotec, Auburn, CA)  after staining with TCR Vβ-specific antibodies 
(Beckman Coulter Inc., Fullerton, CA). 
 
Flow cytometry.  Analysis of T cells was performed using directly conjugated 
monoclonal antibodies obtained from BD Biosciences (San Jose, CA), eBioscience (San 
Diego, CA), Biolegend (San Diego, CA) or R&D Systems (Minneapolis, MN). Vβ staining 
was performed using the IOtest Beta Mark TCR V beta Repertoire kit (Beckman Coulter) 
as per manufacturer’s instructions. Isotype-matched negative control antibodies were 
used to set the gates for positive staining. For analysis of cytokine production, T cells 
were stimulated with either control medium or 50 ng/ml PMA (Sigma Aldrich, Allentown, 
PA) and 750 ng/ml ionomycin (Life Technologies, Grand Island, NY) plus 10 μg/ml 
Brefeldin A (BD) for four hours. Cells were surface stained, fixed, permeabilized, stained 
with anti-cytokine antibodies, and examined by flow cytometry. Analysis was performed 
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on Becton Dickinson FACSCanto instruments and data were analyzed using FACSDiva 
software (V5.1).  
 
DC priming of clonal and non-clonal T cells from CTCL patients.  The 6-sulfo 
LacNAc-expressing dendritic cells (slanDC) were isolated as previously described (19). 
LPS (Sigma Aldrich) was used at 100 ng/ml. For T cell priming, LPS-stimulated dendritic 
cells were harvested and co-cultured with autologous clonal and non-clonal T cells from 
CTCL patients in the presence of 1 ng/ml of staphylococcal enterotoxin B (Sigma 
Aldrich). Following 12 days of culture, T cells were restimulated for intracytoplasmatic 
FACS analysis with PMA and ionomycin. 
 
Co-cultures of healthy PBMC with L-CTCL cells.  2x106/ml PBMC from healthy 
donors (including lymphocytes, monocytes, basophils and dendritic cells) were co-
cultured over 12 days with 1x106/ml fluorescently labelled PBMC from L-CTCL patients 
in Iscove's Modification of Dulbecco's Media (Mediatech, Manassus, VA) supplemented 
with 20% heat-inactivated fetal calf serum, antibiotics and L-glutamine. 100 IU/ml IL-2 
and 15ng/ml IL-15 (Peprotech, Rocky Hill, NJ) were supplemented every other day. 
Where indicated, only cell-substrate, but not direct cell-cell, interaction was allowed, and 
transwell inserts (Corning Inc. Corning, NY) were used to separate L-CTCL from healthy 
PBMC. 
 
Statistical analysis.  For studies described in Fig. 1, the non-parametric Kruskal-Wallis 
test and Dunn’s test were used for comparisons between the three groups. For studies 
described in Fig. 2-5, a standard two-sample Student’s t-test was used. The data were 
previously tested for normal distribution (Shapiro-Wilk test) and homogeneity of variance. 
One-way between group analysis of variance (ANOVA) was used for statistical analysis 
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of differences between three or more groups. P values ≤0.05 were considered as 
significant. 
 
 
 
Results 
 
Both benign and malignant T cells are Th2-biased in patients with L-CTCL. CTCL 
has been proposed to be a malignancy of FOXP3+ regulatory T cells (Tregs) but more 
recent studies showed that only a subset of patients had malignant T cells with a Treg 
phenotype (8, 20, 21).  We identified 12 patients in whom the malignant T cell clone 
could be conclusively identified by staining with commercially available TCR Vβ 
antibodies and analyzed benign and malignant T cells by flow cytometry (Fig. 1A). This 
approach allows direct analysis of the phenotype and functional characteristics of the 
malignant T cell clone while at the same time providing similar information about 
remaining benign T cells. 
 We studied cytokine production and found that both the benign and malignant T cells 
in L-CTCL patients were strongly Th2-biased. Both benign and malignant T cells from L-
CTCL patients produced markedly higher levels of IL-4 than T cells from healthy 
individuals (Fig. 1 A,B). A mean 42.7% of malignant T cells (SEM 7.8, n=12), and 28.1% 
of benign T cells (SEM 7.0, n=12), produced IL-4 in patients with L-CTCL, compared 
with 0.65% of T cells from healthy individuals (SEM 0.18, n=12). IL-13 production was 
significantly higher in malignant T cells and in the benign T cells of five patients and IL-
10 production was also increased in malignant clones.  Th1 responses were globally 
decreased in both benign and malignant T cells from L-CTCL patients, with significantly 
reduced production of IFNγ in both populations (Fig. 1). Production of TNFα was also 
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markedly decreased in both the benign and malignant T cells from L-CTCL patients 
compared to normal controls (Fig. 1).  In a subset of patients, malignant T cell clones 
produced more IL-2 (Fig. 1), consistent with a report that malignant T cells in L-CTCL 
have a phenotype suggestive of central memory T cells, a cell type known to use 
autocrine production of IL-2 to maintain survival (22, 23). However, given the 
heterogeneity among patients, this result was not statistically significant. 
 
Benign T cells show enhanced Th1 and reduced Th2 responses when cultured 
separately from clonal malignant T cells. Th2 cells can suppress the production of 
Th1 cytokines by other T cells in vitro (24, 25). To evaluate if clonal malignant T cells 
suppress benign T cell responses, we separated non-clonal benign from clonal 
malignant T cells from the blood of L-CTCL patients using magnetic beads and cultured 
these T cells separately in the presence of autologous LPS-activated DC. IFNγ 
production increased and IL-4 production decreased in non-clonal T cells cultured away 
from the malignant clone whereas clonal T cells showed no significant changes in IFNγ 
or IL-4 production (Fig. 2 A,B). RT-PCR analyses demonstrated that expression of the 
Th2-associated transcription factor GATA-3 declined and expression of the Th1-
associated transcription factor t-BET increased in benign T cells after culture away from 
the malignant clone (Fig. 2C). In clonal malignant T cells, there was no change in the 
expression of GATA-3 and t-BET after separate culture.  Expression of the Th17-
associated transcription factor RORc was low in both malignant and benign T cells 
before and after culture.  T cells isolated from the skin lesions of patients with L-CTCL 
had similar responses; IFNγ increased in non-clonal T cells after separate co-culture but 
remained unchanged in malignant T cells (Fig. 2D).  
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IL-4 and IL-13 produced by L-CTCL T cells suppress Th1 responses of T cells from 
healthy donors.  To evaluate the ability of L-CTCL T cells to suppress non-Th2 
cytokine production, we cultured PBMC from healthy individuals with fluorescently 
labelled PBMC from L-CTCL patients with a high malignant T cell burden. Co-culture 
was performed in direct contact or in transwell systems which separated healthy from L-
CTCL cells. After co-culture with L-CTCL cells, T cells from healthy patients showed 
reduced production of IFNγ (Fig. 3). Suppression was observed in both direct contact 
and transwell cultures, suggesting a soluble factor was responsible for Th1 suppression. 
To determine if Th2 cytokines produced by malignant T cells were responsible for the 
suppression of IFNγ production in healthy T cells, we included neutralizing antibodies to 
IL-4 and IL-13 in transwell co-cultures of L-CTCL and healthy PBMC. Results 
demonstrated that neutralization of IL-4 and IL-13 restored the production of IFNγ to 
baseline levels (Fig. 4). 
 
A variety of modalities that reduce tumor burden enhance the Th1 responses of 
benign T cells 
It has been previously reported that immunomodulatory therapies for CTCL, including 
IFN-α2b  and extracorporeal photopheresis, led to enhanced Th1 responses in 
responding patients (26). IFN-α2b  and extracorporeal photopheresis both have 
immunomodulatory effects beyond their ability to reduce the number of malignant T 
cells. If Th2 cytokines produced by malignant T cells are indeed responsible for the 
decreased Th1 responses, pruritus, susceptibility to infections and benign T cell Th2 
skewing observed in these individuals, then a variety of treatment modalities that have in 
common only the depletion of malignant T cells should all produce enhanced Th1 
responses, regardless of the underlying mechanism of action of the therapy used. To 
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study this issue, we evaluated the cytokine production of benign T cells before and after 
therapy with a variety of treatment modalities (Fig. 5). We found that successful therapy 
with a variety modalities, including UVB phototherapy, extracorporeal photopheresis, low 
dose alemtuzumab and systemic chemotherapy with gemcitabine, all had similar effects 
on the cytokine production of benign T cells. In all therapies and in all patients examined, 
when the number of circulating T cells declined, benign T cells subsequently produced 
less IL-4 and more IL-2 and IFNγ (Fig. 5). In addition to the patients shown, similar 
findings were observed in six additional patients treated with a combination of therapies 
that also included topical corticosteroids, electron beam therapy and narrow band UVB 
(data not shown). In all patients included in this analysis, complete remission of at least 
4 months was achieved. With respect to the patients shown in Fig. 5, the first patient 
(Fig. 5A) remains in remission on UVB and topical steroids but photopheresis was 
discontinued. Following a complete remission with alemtuzumab therapy, the second 
patient (Fig. 5B) subsequently relapsed with progressive skin disease not controlled by 
alemtuzumab and ultimately died from progressive disease. The third patient (Fig. 5C) 
experienced a complete remission following gemcitabine, and underwent stem cell 
transplantation.  
 
Discussion 
 
There has been some disagreement regarding the cytokine production and functional 
polarization of malignant T cells in L-CTCL. L-CTCL has been proposed to be a uniform 
malignancy of FOXP3+ regulatory T cells, Th17 cells and Th2 cells (8-10). All of the 
patients in our cohort showed a marked Th2 bias in malignant T cells, in agreement with 
earlier studies that the vast majority of patients with L-CTCL have Th2 biased malignant 
T cells (9, 14-17, 27). L-CTCL patients have characteristics suggestive of a Th2 driven 
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immunologic process, including elevated levels of IgE and IgA, eosinophilia and reduced 
Th1 responses (11-13).  These patients also suffer from marked pruritus of the skin, high 
rates of colonization with Staphylococcus aureus and a high susceptibility to cutaneous 
infections, similar to patients with atopic dermatitis, a prototypic Th2 disease (28).  We 
did not observe any patients with malignant T cells of a Th17 phenotype. 
 Malignant T cells in L-CTCL have a phenotype suggestive of skin tropic central 
memory T cells (TCM) (22).  TCM are highly migratory, recirculate between the blood, skin 
and lymph nodes, have a high proliferative potential, are markedly resistant to apoptosis 
and have a variety of cytokine production profiles (23). The TCM phenotype of these cells 
helps to explain why L-CTCL patients develop erythroderma, peripheral blood disease 
and lymphadenopathy. However, one might expect that malignant T cells would have a 
heterogeneous pattern of cytokine production that reflects the diverse population of TCM 
from which they arise. The fact that the vast majority of patients have strongly Th2 
biased malignant T cells is striking. We found that the Th2 bias of the malignant T cells 
was remarkably stable in vitro, suggesting this bias may result from intrinsic 
abnormalities of the cell or from autocrine factors, for example galectin-1 produced by 
malignant T cells which has previously been implicated in the Th2 skewing of the 
malignant clone (17).  It may also be that Th2 malignant T cell clones predominate in L-
CTCL because they are remarkably effective in suppressing anticancer Th1 responses 
and therefore have a survival advantage.  
 We were surprised to find that the benign T cells remaining in the circulation of 
patients with L-CTCL were significantly different from those found in normal individuals. 
There was a striking and consistent Th2 bias even among the benign T cells in these 
patients, as well as a reduction in the production of Th1 cytokines (Fig. 1). These results 
demonstrate that a global Th2 bias exists in these patients that leads to skewing of the 
entire T cell repertoire, both benign and malignant, toward enhanced production of Th2 
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cytokines. This overproduction of Th2 cytokines by both malignant and benign T cells 
likely contributes to the pruritus, reduced Th1 responses and the susceptibility to 
infections observed in these patients.  
 The remaining non-clonal benign T cells in patients with L-CTCL would be expected 
to have a variety of cytokine production capacities. Given the known ability of Th2 cells 
to suppress Th1 responses and to force a Th2 bias on other T cells (24, 25),  we 
hypothesized that the malignant T cells may suppress the activity of benign T cells, 
silencing Th1 responses, as has been suggested previously (26). Indeed, when we 
separated and cultured non-clonal T cells from the blood and skin lesions of patients 
away from the malignant clone, we observed improved Th1 responses (Fig. 2). When we 
co-cultured T cells from healthy individuals with L-CTCL T cells, we saw a marked 
inhibition of Th1 responses (Fig. 3, 4). Incubation of co-cultures with neutralizing 
antibodies to IL-4 and IL-13 restored Th1 responses, suggesting Th2 cytokines 
produced by malignant T cells may be directly responsible for the suppression of Th1 
responses we observed in our patients and in T cells from healthy donors. If so, 
successful treatment of patients with CTCL should reduce Th2 and enhance Th1 
responses, as a previous study of 3 patients suggested (26). 
 To study this question, we evaluated L-CTCL patients treated with a variety of 
modalities that had in common only reduction in the number of circulating malignant T 
cells. Regardless of the underlying mechanism of action of particular therapies, 
treatments that reduced malignant T cell burden were invariably associated with 
enhanced Th1 responses (Figure 5). Although circumstantial, our results suggest that 
Th2 cytokines produced by malignant T cells play a critical role in suppressing Th1 
responses in our patients. 
 In summary, we report a marked Th2 bias in both the benign and malignant T cells in 
patients with L-CTCL and we find that Th2 cytokine production by the malignant clone 
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likely suppresses Th1 responses in these patients. Th1 responses improved in vitro 
when the benign T cells were cultured away from the malignant clone, when IL-4 and IL-
13 activities were blocked in vitro with neutralizing antibodies, and in patients 
themselves after treatment with therapies that reduced the number of circulating 
malignant T cells. The suppression of Th1 responses in these patients by IL-4 and IL-13 
suggests that neutralization of these cytokines may be beneficial in enhancing immune 
responses. Aeroderm, a recombinant small protein antagonist of the IL-4/IL-13 receptor 
formulated for skin injection, was previously in clinical trials for the treatment of severe 
AD (29). By inhibiting Th2 responses and enhancing Th1 responses, IL-4/IL-13 
antagonists have the potential to enhance immune responses to both skin pathogens 
and to the malignant T cells themselves. 
 
Acknowledgments 
The authors would like to thank the patients who donated the blood and skin samples 
that made this work possible.  
 
Disclosure of Potential Conflicts of Interest  
The authors report no potential conflicts of interest. 
 
Authorship 
E.G. and R.W. carried out experiments, analyzed data, prepared figures and edited the 
manuscript, J.T., Y.J. M.D., A.G and C.S. participated in sample preparation, A.H.R. 
provided funding and advice, K. S. provided reagents and critical advice for dendritic cell 
isolation, J.A.D., M.T, D.C.F. and T.S.K. supplied patient samples and T.S.K. also 
provided critical experimental advice. R.A.C. designed the experiments, analyzed data, 
prepared figures and drafted the manuscript. 
14 
 
Grant Support 
This work was supported by a generous charitable contribution from Edward P. 
Lawrence, Esq., a Damon Runyon Clinical Investigator Award (to RAC) R01 AR056720 
(to RAC) and R03 MH095529 (to RAC), the SPORE in Skin Cancer P50 CA9368305 
NIH/NCI (to TSK), R01 A1025082 NIH/NIAID (to TSK), R01 AI097128 (to TSK and RAC), 
R01 CA122569 (to AHR) and by a Special Fellow Award from the Leukemia & 
Lymphoma Society (to RW). Grant support GU1271/2-1 (to EG) was provided by the 
German Research Foundation (DFG) and salary support for CS was provided by the 
Swiss National Science Foundation and the Fondation Rene Touraine. 
 
References: 
1. Girardi M, Heald PW, Wilson LD. The pathogenesis of mycosis fungoides. The 
New England journal of medicine. 2004;350:1978-88. 
2. Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, et al. 
Immunopathogenesis and therapy of cutaneous T cell lymphoma. The Journal of 
clinical investigation. 2005;115:798-812. 
3. NCCN Clinical Practice Guidelines in Oncology™ Non-Hodgkin’s Lymphomas 
Version 3.2009 2009  [cited 2009 October 22, 2009]; To view the most recent 
and complete version of the NCCN Guidelines, go online to NCCN.org.]. 
Available from:  
4. Willemze R, Kerl H, Sterry W, Berti E, Cerroni L, Chimenti S, et al. EORTC 
classification for primary cutaneous lymphomas: a proposal from the Cutaneous 
Lymphoma Study Group of the European Organization for Research and 
Treatment of Cancer. Blood. 1997;90:354-71. 
15 
5. Scarisbrick JJ, Whittaker S, Evans AV, Fraser-Andrews EA, Child FJ, Dean A, et 
al. Prognostic significance of tumor burden in the blood of patients with 
erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001;97:624-30. 
6. Vidulich KA, Talpur R, Bassett RL, Duvic M. Overall survival in erythrodermic 
cutaneous T-cell lymphoma: an analysis of prognostic factors in a cohort of 
patients with erythrodermic cutaneous T-cell lymphoma. International journal of 
dermatology. 2009;48:243-52. 
7. Talpur R, Singh L, Daulat S, Liu P, Seyfer S, Trynosky T, et al. Long-term 
outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 
1982 to 2009. Clin Cancer Res. 2012;18:5051-60. 
8. Berger CL, Tigelaar R, Cohen J, Mariwalla K, Trinh J, Wang N, et al. Cutaneous 
T-cell lymphoma: malignant proliferation of T-regulatory cells. Blood. 
2005;105:1640-7. 
9. Dummer R, Heald PW, Nestle FO, Ludwig E, Laine E, Hemmi S, et al. Sezary 
syndrome T-cell clones display T-helper 2 cytokines and express the accessory 
factor-1 (interferon-gamma receptor beta-chain). Blood. 1996;88:1383-9. 
10. Krejsgaard T, Ralfkiaer U, Clasen-Linde E, Eriksen KW, Kopp KL, Bonefeld CM, 
et al. Malignant cutaneous T-cell lymphoma cells express IL-17 utilizing the 
Jak3/Stat3 signaling pathway. The Journal of investigative dermatology. 
2011;131:1331-8. 
11. Rook AH, Heald P. The immunopathogenesis of cutaneous T-cell lymphoma. 
Hematol Oncol Clin North Am. 1995;9:997-1010. 
12. Rook AH, Vowels BR, Jaworsky C, Singh A, Lessin SR. The 
immunopathogenesis of cutaneous T-cell lymphoma. Abnormal cytokine 
production by Sezary T cells. Arch Dermatol. 1993;129:486-9. 
16 
13. Tendler CL, Burton JD, Jaffe J, Danielpour D, Charley M, McCoy JP, et al. 
Abnormal cytokine expression in Sezary and adult T-cell leukemia cells 
correlates with the functional diversity between these T-cell malignancies. 
Cancer research. 1994;54:4430-5. 
14. Papadavid E, Economidou J, Psarra A, Kapsimali V, Mantzana V, Antoniou C, et 
al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the 
evaluation of patients with mycosis fungoides and Sezary syndrome. The British 
journal of dermatology. 2003;148:709-18. 
15. Vowels BR, Lessin SR, Cassin M, Jaworsky C, Benoit B, Wolfe JT, et al. Th2 
cytokine mRNA expression in skin in cutaneous T-cell lymphoma. The Journal of 
investigative dermatology. 1994;103:669-73. 
16. Kari L, Loboda A, Nebozhyn M, Rook AH, Vonderheid EC, Nichols C, et al. 
Classification and prediction of survival in patients with the leukemic phase of 
cutaneous T cell lymphoma. The Journal of experimental medicine. 
2003;197:1477-88. 
17. Cedeno-Laurent F, Watanabe R, Teague JE, Kupper TS, Clark RA, Dimitroff CJ. 
Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of 
nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood. 
2012;119:3534-8. 
18. Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, et al. WHO-
EORTC classification for cutaneous lymphomas 
10.1182/blood-2004-09-3502. Blood. 2005;105:3768-85. 
19. Schakel K, von Kietzell M, Hansel A, Ebling A, Schulze L, Haase M, et al. Human 
6-sulfo LacNAc-expressing dendritic cells are principal producers of early 
interleukin-12 and are controlled by erythrocytes. Immunity. 2006;24:767-77. 
17 
20. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Eriksen KW, Mathiesen 
AM, et al. Malignant Tregs express low molecular splice forms of FOXP3 in 
Sezary syndrome. Leukemia : official journal of the Leukemia Society of America, 
Leukemia Research Fund, UK. 2008;22:2230-9. 
21. Heid JB, Schmidt A, Oberle N, Goerdt S, Krammer PH, Suri-Payer E, et al. 
FOXP3+CD25- tumor cells with regulatory function in Sezary syndrome. The 
Journal of investigative dermatology. 2009;129:2875-85. 
22. Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis 
fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct 
clinical behaviors. Blood. 2010;116:767-71. 
23. Sallusto F, Geginat J, Lanzavecchia A. Central Memory and Effector Memory T 
Cell Subsets: Function, Generation, and Maintenance. Annual review of 
immunology. 2004;22:745-63. 
24. Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine 
secretion lead to different functional properties. Annual review of immunology. 
1989;7:145-73. 
25. Paul WE, Seder RA. Lymphocyte responses and cytokines. Cell. 1994;76:241-51. 
26. Yoo EK, Cassin M, Lessin SR, Rook AH. Complete molecular remission during 
biologic response modifier therapy for Sezary syndrome is associated with 
enhanced helper T type 1 cytokine production and natural killer cell activity. 
Journal of the American Academy of Dermatology. 2001;45:208-16. 
27. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production 
by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 
cells. The Journal of investigative dermatology. 1992;99:90-4. 
28. Jackow CM, Cather JC, Hearne V, Asano AT, Musser JM, Duvic M. Association 
of erythrodermic cutaneous T-cell lymphoma, superantigen-positive 
18 
Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. 
Blood. 1997;89:32-40. 
29. Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-
4 variant on late phase asthmatic response to allergen challenge in asthmatic 
patients: results of two phase 2a studies. Lancet. 2007;370:1422-31. 
 
 
19 
Figure legends 
Fig. 1. Both benign and malignant T cells are strongly Th2-biased in patients with 
L-CTCL.  Clonal malignant T cells were definitively identified by staining with TCR Vβ 
antibodies specific for each patient's malignant clone. The cytokine production of 
malignant (clonal) and benign (non-clonal) T cells was evaluated by stimulating cells with 
PMA and ionomycin, surface staining for CD3, CD4 and the malignant TCR Vβ 
clonotype, then performing intracellular cytokine staining followed by flow cytometry 
analysis. (A) Representative results from patient 330 are shown. Th2 cytokines, 
including IL-4 and IL-13, were produced at high levels by both benign and malignant T 
cells. (B) Th2 cytokine production was elevated and Th1 cytokine production was 
reduced in both the benign (non-clonal) and malignant (clonal) T cells from L-CTCL 
patients as compared to normal controls. 12 healthy individuals and 12 patients with L-
CTCL are shown. Increased IL-4 production and loss of IFNγ and TNFα production were 
observed in both malignant and benign T cells from patients with L-CTCL. The 
production of IL-13 and IL-10 was also elevated in the malignant clones. ** p<0.01, *** 
p<0.001. 
 
Fig. 2. Benign T cells show reduced Th2 and enhanced Th1 responses when 
cultured separately from clonal malignant T cells.  (A, B) Non-clonal benign and 
clonal malignant T cells were isolated from the blood of L-CTCL patients using magnetic 
beads. Clonal and non-clonal T cells were cultured separately with LPS-activated 
autologous DC for 12 days and then assayed for cytokine production by intracellular flow 
cytometry. IFNγ production increased and IL-4 production decreased in non-clonal T 
cells cultured away from the malignant clone but clonal T cells showed no significant 
changes in IFNγ or IL-4 production. Representative dot plots (A) and the mean and SEM 
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of three L-CTCL patients (B) are shown. (C) Changes in the expression of Th1- and Th2-
associated transcription factors parallel observed changes in cytokine production in 
benign and malignant T cells cultured separately. In benign T cells cultured away from 
the malignant clone, expression of GATA-3 (Th2) decreased and expression of t-BET 
(Th1) increased whereas expression levels of both transcription factors remained 
unchanged in malignant T cells. Expression of RORγ (Th17) was low in both cell 
populations both before and after culture. (D) Th1 responses are also enhanced in 
lesional skin T cells cultured away from the malignant clone. T cells were isolated from 
lesional skin, separated into non-clonal and clonal T cells and then cultured separately 
with LPS-activated autologous DC. Non-clonal T cells from lesional skin showed a 
marked enhancement of IFN-γ production after culture away from the malignant clone. 
*p<0.05. 
 
Fig. 3. Soluble factors from L-CTCL T cells suppress Th1 responses of PBMC from 
healthy donors. PBMC from healthy donors were co-cultured with PBMC from L-CTCL 
patients with high malignant T cell burden for 12 days either in direct contact or in a 
transwell system, then assayed for cytokine production by flow cytometry. Production of 
IFN-γ was significantly reduced after culture with L-CTCL PBMC in both direct contact 
and in transwell systems. (A) Representative dot plots and (B) mean and SEM from 3 
independent experiments are shown. ***p<0.001. 
 
Fig. 4. Neutralization of IL-4 and IL-13 restores Th1 responses. PBMC from healthy 
donors were co-cultured with L-CTCL PBMC using a transwell system with or without 
neutralizing antibodies to IL-4 and IL-13 or appropriate isotype controls.  Cytokine 
production was then determined by flow cytometry. Dot plots are gated to show only 
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healthy CD4+ T cells. Representative data from one experiment (A) and cumulative data 
from 3 independent experiments (B) are shown. **p<0.005, ***p<0.001. 
 
Fig. 5. A variety of treatment modalities that reduce tumor burden enhance Th1 
responses of benign T cells in vivo. (A) Clinical photos of patients before and after the 
indicated therapies are shown. (B) All modalities reduced the number of circulating 
malignant T cells (red) and (C) all were associated with decreased production of IL-4 
and increased production of both IFNγ and IL-2 by benign T cells after therapy (after tx).  
 
Patient  
ID # Clone Age Gender 
CD4/CD8 
Ratio 
Absolute CD4 
count Treatments 
Disease 
duration 
[years] 
395 Vβ17 67 M 31 8,323 I, TS, D, G, ECP  3 
326 Vβ7.2 80 M 10.2 2,893 I, ECP, B, A 5 
489 Vβ13.2 46 M 17.8 1,991 A, G 1 
414 Vβ13.1 72 M 18 2,442 ECP, T, A, V, D, P, R, G   0.5 
478 Vβ17 56 F 7.18 2,546 TS, ECP 1 
484 Vβ2 56 F 9.43 2,383 TS, ECP, SS 2 
279 Vβ13.1 72 M 13.5 2,504 D, B, ECP, PUVA, I, A,V, G, 5 
475 Vβ2 70 F 3.1 1,230 UVB, ECP, A 7 
382 Vβ1 75 F 2.67 1,029 TS, UVB 9 
372 Vβ5.2 64 F 94 11,083 PUVA, ECP, UVB, TS, I 12 
365 Vβ17 83 M 23 3,671 B  4 
330 Vβ13.1 72 M 18.6 5,028 UVB, TS, B 8 
292 Vβ17 67 M 32.3 5,356 PUVA, UVB, TS, I, ECP, B, G 13 
119 Vβ13.1 78 F 14.5 2,800 PUVA, D, I, ECP, V, B 6 
99 Vβ17 81 F 12.56 3,530 PUVA, UVB, TS 7 
44 Vβ21.3 96 F 6.52 1,495 I, SS 16 
472 Vβ2 88 M 93 3,798 ECP, B, PUVA, A  3 
 
Table 1. Clinical patient characteristics. I – IFN-α−2a, ECP – extracorporeal photochemotherapy, V – vorinostat, B – bexarotene, D – 
denileukin diftitox, TS – topical steroids, SS – systemic steroids, G – gemcitabine, A – alemtuzumab, P – pralatraxate, R – romidepsin, PUVA – 
psoralen + UVA treatment 
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 Statement of translational relevance 
 
Patients with leukemic cutaneous T cell lymphoma (L-CTCL) have an average 3 year 
survival, die most commonly from infection and have clinical abnormalities consistent 
with a Th2-driven immunologic process. We find both malignant and benign T cells in L-
CTCL are markedly Th2 biased, demonstrating a global Th2 skewing. Culture of benign 
T cells away from the malignant clone reduced Th2 and enhanced Th1 responses but 
separate culture had no effect on malignant T cells. Co-culture of healthy T cells with L-
CTCL T cells reduced IFNγ production and neutralizing antibodies to IL-4 and IL-13 
restored Th1 responses. In patients, enhanced Th1 responses were observed following 
a variety of treatment modalities that reduced malignant T cell burden suggesting that 
Th2 cytokines produced by malignant T cells play a critical role in down-regulating Th1 
responses in vivo. Results suggest that neutralization of Th2 cytokines may be beneficial 
in enhancing immune responses both to pathogens and to the malignancy itself. 
3 
Abstract 
Purpose: In leukemic CTCL (L-CTCL) malignant T cells accumulate in the blood and 
give rise to widespread skin inflammation. Patients have intense pruritus, increased IgE, 
decreased Th1 responses and most die from infection. Depleting malignant T cells while 
preserving normal immunity is a clinical challenge. L-CTCL has been variably described 
as a malignancy of regulatory, Th2 and Th17 cells.  
Experimental design: We analyzed phenotype and cytokine production in malignant 
and benign L-CTCL T cells, characterized the effects of malignant T cells on healthy T 
cells and studied the immunomodulatory effects of treatment modalities in L-CTCL 
patients.  
Results: 12/12 L-CTCL patients overproduced Th2 cytokines. Remaining benign T cells 
were also strongly Th2 biased, suggesting a global Th2 skewing of the T cell repertoire. 
Culture of benign T cells away from the malignant clone reduced Th2 and enhanced Th1 
responses but separate culture had no effect on malignant T cells. Co-culture of healthy 
T cells with L-CTCL T cells reduced IFNγ production and neutralizing antibodies to IL-4 
and IL-13 restored Th1 responses. In patients, enhanced Th1 responses were observed 
following a variety of treatment modalities that reduced malignant T cell burden.  
Conclusions: A global Th2 bias exists in both benign and malignant T cells in L-CTCL 
and may underlie the infectious susceptibility of patients.  Th2 cytokines from malignant 
cells strongly inhibited Th1 responses. Our results suggest therapies that inhibit Th2 
cytokine activity, by virtue of their ability to improve Th1 responses, may have the 
potential to enhance both anti-cancer and anti-pathogen responses. 
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Introduction 
 Cutaneous T cell lymphomas (CTCLs) are a heterogeneous group of non-Hodgkin’s 
lymphomas arising from malignant transformation of T cells that home to and populate 
the skin (1, 2). In leukemic variants of CTCL (L-CTCL), including Sézary syndrome, 
malignant T cells accumulate in the blood and lymph nodes and give rise to diffuse 
erythema of the skin. L-CTCL is often refractory to multiple therapies and such patients 
often require hematopoietic stem cell transplantation (3).  The median survival for 
patients with L-CTCL is 3 years and patients die most commonly from infections (4, 5).   
 CTCL has been proposed to be a malignancy of three separate T cell populations: 
FOXP3+ Treg, Th2 T cells and Th17 T cells (6-8).  Clinically, patients with L-CTCL have 
abnormalities suggestive of a Th2 driven immunologic process, including decreased 
antigen specific T cell responses, impaired cell mediated cytotoxicity, peripheral 
eosinophilia, and elevated levels of serum IgE and IgA (9-11). Prior studies have shown 
increased levels of Th2 cytokines and Th2 associated genes in T cells from patients with 
L-CTCL (7, 12-15) but a recent report claims that malignant T cells in the disease are 
actually Th17 biased (8). 
 We performed comprehensive analyses of the cytokine production of benign and 
malignant T cells from L-CTCL with identifiable malignant T cell clones. We report here 
that both malignant and benign T cells in L-CTCL patients were strongly Th2 biased, that 
this bias was intrinsic in malignant T cells but extrinsic in benign cells and that inhibition 
of Th2 cytokines led to recovery of Th1 responses in benign T cells. 
 
Materials and Methods 
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Blood samples. The protocols of this study were performed in accordance with the 
Declaration of Helsinki and were approved by the Institutional Review Board of the 
Partners Human Research Committee (Partners Research Management, Boston, 
MA, USA). Blood from healthy individuals was obtained as discarded tissue following 
leukopheresis. Blood and lesional skin from patients with CTCL were obtained from 
patients seen at the Dana-Farber/Brigham and Women’s Cancer Center Cutaneous 
Lymphoma Program. L-CTCL patients described in this manuscript met the WHO-
EORTC criteria for L-CTCL/SS (16). Patient characteristics are included in Table I. 
PBMC were isolated by ficoll centrifugation. For isolation of malignant and benign T 
cells, clonal and non-clonal CD4+ T cells from CTCL patients were isolated using Vβ 
staining antibodies (Beckman Coulter Inc., Fullerton, CA), anti-fluorochrome MicroBeads 
and CD4+ T Cell Isolation Kit (Miltenyi Biotec, Auburn, CA), according to manufacturer’s 
instructions. 
 
Flow cytometry.  Analysis of T cells was performed using directly conjugated 
monoclonal antibodies obtained from BD Biosciences (San Jose, CA), eBioscience (San 
Diego, CA), Biolegend (San Diego, CA) or R&D Systems (Minneapolis, MN). Vβ staining 
was performed using the IOtest Beta Mark TCR V beta Repertoire kit (Beckman Coulter) 
as per manufacturer’s instructions. Isotype-matched negative control antibodies were 
used to set the gates for positive staining. For analysis of cytokine production, T cells 
were stimulated with either control medium or 50 ng/ml PMA (Sigma Aldrich, Allentown, 
PA) and 750 ng/ml ionomycin (Life Technologies, Grand Island, NY) plus 10 μg/ml 
Brefeldin A (BD) for four hours. Cells were surface stained, fixed, permeabilized, stained 
with anti-cytokine antibodies, and examined by flow cytometry. Analysis of flow 
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cytometry samples was performed on Becton Dickinson FACSCanto instruments and 
data were analyzed using FACSDiva software (V5.1).  
 
DC priming of clonal and non-clonal T cells from CTCL patients.  The 6-sulfo 
LacNAc-expressing dendritic cells (slanDC) were isolated as previously described (17). 
LPS (Sigma Aldrich) was used at 100 ng/ml. For T cell priming, LPS-stimulated dendritic 
cells were harvested and co-cultured with autologous clonal and non-clonal T cells from 
CTCL patients in the presence of 1 ng/ml of staphylococcal enterotoxin B (Sigma 
Aldrich). Following 12 days of culture, T cells were restimulated for intracytoplasmatic 
FACS analysis with PMA and ionomycin. 
 
Co-cultures of healthy PBMC with L-CTCL cells.  2x106/ml PBMC from healthy 
donors (including lymphocytes, monocytes, basophils and dendritic cells) were co-
cultured over 12 days with 1x106/ml fluorescently labelled PBMC from L-CTCL patients 
in Iscove's Modification of Dulbecco's Media (Mediatech, Manassus, VA) supplemented 
with 20% heat-inactivated fetal calf serum, antibiotics and L-glutamine. 100 IU/ml IL-2 
and 15ng/ml IL-15 (Peprotech, Rocky Hill, NJ) were supplemented every other day. 
Where indicated, only cell-substrate, but not direct cell-cell, interaction was allowed, and 
transwell inserts (Corning Inc. Corning, NY) were used to separate L-CTCL from healthy 
PBMC. 
 
Statistical analysis.  For studies described in Fig. 1, the non-parametric Kruskal-Wallis 
test and Dunn’s test were used for comparisons between the three groups. For studies 
described in Fig. 2-5, a standard two-sample Student’s t-test was used. The data were 
previously tested for normal distribution (Shapiro-Wilk test) and homogeneity of variance. 
One-way between group analysis of variance (ANOVA) was used for statistical analysis 
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of differences between three or more groups. P values ≤0.05 were considered as 
significant. 
 
 
 
Results 
 
Both benign and malignant T cells are Th2-biased in patients with L-CTCL. CTCL 
has been proposed to be a malignancy of FOXP3+ regulatory T cells (Tregs) but more 
recent studies showed that only a subset of patients had malignant T cells with a Treg 
phenotype (6, 18, 19).  We identified 12 patients in whom the malignant T cell clone 
could be conclusively identified by staining with commercially available TCR Vβ 
antibodies and analyzed benign and malignant T cells by flow cytometry (Fig. 1A). This 
approach allows direct analysis of the phenotype and functional characteristics of the 
malignant T cell clone while at the same time providing similar information about 
remaining benign T cells. 
 We studied cytokine production and found that both the benign and malignant T cells 
in L-CTCL patients were strongly Th2-biased. Both benign and malignant T cells from L-
CTCL patients produced markedly higher levels of IL-4 than T cells from healthy 
individuals (Fig. 1 A,B). A mean 42.7% of malignant T cells (SEM 7.8, n=12), and 28.1% 
of benign T cells (SEM 7.0, n=12), produced IL-4 in patients with L-CTCL, compared 
with 0.65% of T cells from healthy individuals (SEM 0.18, n=12). IL-13 production was 
significantly higher in malignant T cells and in the benign T cells of five patients and IL-
10 production was also increased in malignant clones.  Th1 responses were globally 
decreased in both benign and malignant T cells from L-CTCL patients, with significantly 
reduced production of IFNγ in both populations (Fig. 1). Production of TNFα was also 
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markedly decreased in both the benign and malignant T cells from L-CTCL patients 
compared to normal controls (Fig. 1).  In a subset of patients, malignant T cell clones 
produced more IL-2 (Fig. 1), consistent with a report that malignant T cells in L-CTCL 
have a phenotype suggestive of central memory T cells, a cell type known to use 
autocrine production of IL-2 to maintain survival (20, 21). However, given the 
heterogeneity among patients, this result was not statistically significant. 
 
Benign T cells show enhanced Th1 and reduced Th2 responses when cultured 
separately from clonal malignant T cells. Th2 cells can suppress the production of 
Th1 cytokines by other T cells in vitro (22, 23). To evaluate if clonal malignant T cells 
suppress benign T cell responses, we separated non-clonal benign from clonal 
malignant T cells from the blood of L-CTCL patients using magnetic beads and cultured 
these T cells separately in the presence of autologous LPS-activated DC. IFNγ 
production increased and IL-4 production decreased in non-clonal T cells cultured away 
from the malignant clone but clonal T cells showed no significant changes in IFNγ or IL-4 
production (Fig. 2 A,B). RT-PCR analyses demonstrated that expression of the Th2-
associated transcription factor GATA-3 declined and expression of the Th1-associated 
transcription factor t-BET increased in benign T cells after culture away from the 
malignant clone (Fig. 2C). In clonal malignant T cells, there was no change in the 
expression of GATA-3 and t-BET after separate culture.  Expression of the Th17-
associated transcription factor RORc was low in both malignant and benign T cells 
before and after culture.  T cells isolated from the skin lesions of patients with L-CTCL 
had similar responses; IFNγ increased in non-clonal T cells after separate co-culture but 
remained unchanged in malignant T cells (Fig. 2D).  
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IL-4 and IL-13 produced by L-CTCL T cells suppress Th1 responses of T cells from 
healthy donors.  To evaluate the ability of L-CTCL T cells to suppress non-Th2 
cytokine production, we cultured PBMC from healthy individuals with fluorescently 
labelled PBMC from L-CTCL patients with a high malignant T cell burden. Co-culture 
was performed in direct contact or in transwell systems which separated healthy from L-
CTCL cells. After co-culture with L-CTCL cells, T cells from healthy patients showed 
reduced production of IFNγ (Fig. 3). Suppression was observed in both direct contact 
and transwell cultures, suggesting a soluble factor was responsible for Th1 suppression. 
To determine if Th2 cytokines produced by malignant T cells were responsible for the 
suppression of IFNγ production in healthy T cells, we included neutralizing antibodies to 
IL-4 and IL-13 in transwell co-cultures of L-CTCL and healthy PBMC. Results 
demonstrated that neutralization of IL-4 and IL-13 restored the production of IFNγ to 
baseline levels (Fig. 4). 
 
A variety of modalities that reduce tumor burden enhance the Th1 responses of 
benign T cells 
It has been previously reported that immunomodulatory therapies for CTCL, including 
IFN-α2b  and extracorporeal photopheresis, led to enhanced Th1 responses in 
responding patients (24). IFN-α2b  and extracorporeal photopheresis both have 
immunomodulatory effects beyond their ability to reduce the number of malignant T 
cells. If Th2 cytokines produced by malignant T cells are indeed responsible for the 
decreased Th1 responses, pruritus, susceptibility to infections and benign T cell Th2 
skewing observed in these individuals, then a variety of treatment modalities that have in 
common only the depletion of malignant T cells should all produce enhanced Th1 
responses, regardless of the underlying mechanism of action of the therapy used. To 
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study this issue, we evaluated the cytokine production of benign T cells before and after 
therapy with a variety of treatment modalities (Fig. 5). We found that successful therapy 
with a variety modalities, including UVB phototherapy, extracorporeal photopheresis, low 
dose alemtuzumab and systemic chemotherapy with gemcitabine, all had similar effects 
on the cytokine production of benign T cells. In all therapies and in all patients examined, 
when the number of circulating T cells declined, benign T cells subsequently produced 
less IL-4 and more IL-2 and IFNγ (Fig. 5). In addition to the patients shown, similar 
findings were observed in six additional patients treated with a combination of therapies 
that also included topical corticosteroids, electron beam therapy and narrow band UVB 
(data not shown).  
 
Discussion 
 
There has been some disagreement regarding the cytokine production and functional 
polarization of malignant T cells in L-CTCL. L-CTCL has been proposed to be a uniform 
malignancy of FOXP3+ regulatory T cells, Th17 cells and Th2 cells (6-8). All of the 
patients in our cohort showed a marked Th2 bias in malignant T cells, in agreement with 
earlier studies that the vast majority of patients with L-CTCL have Th2 biased malignant 
T cells (7, 12-15, 25). L-CTCL patients have characteristics suggestive of a Th2 driven 
immunologic process, including elevated levels of IgE and IgA, eosinophilia and reduced 
Th1 responses (9-11).  These patients also suffer from marked pruritus of the skin, high 
rates of colonization with Staphylococcus aureus and a high susceptibility to cutaneous 
infections, similar to patients with atopic dermatitis, a prototypic Th2 disease (26).  We 
did not observe any patients with malignant T cells of a Th17 phenotype. 
 Malignant T cells in L-CTCL have a phenotype suggestive of skin tropic central 
memory T cells (TCM) (20).  TCM are highly migratory, recirculate between the blood, skin 
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and lymph nodes, have a high proliferative potential, are markedly resistant to apoptosis 
and have a variety of cytokine production profiles (21). The TCM phenotype of these cells 
helps to explain why L-CTCL patients develop erythroderma, peripheral blood disease 
and lymphadenopathy. However, one might expect that malignant T cells would have a 
heterogeneous pattern of cytokine production that reflects the diverse population of TCM 
from which they arise. The fact that the vast majority of patients have strongly Th2 
biased malignant T cells is striking. We found that the Th2 bias of the malignant T cells 
was remarkably stable in vitro, suggesting this bias may result from intrinsic 
abnormalities of the cell or from autocrine factors, for example galectin-1 produced by 
malignant T cells which has previously been implicated in the Th2 skewing of the 
malignant clone (15).  It may also be that Th2 malignant T cell clones predominate in L-
CTCL because they are remarkably effective in suppressing anticancer Th1 responses 
and therefore have a survival advantage.  
 We were surprised to find that the benign T cells remaining in the circulation of 
patients with L-CTCL were significantly different from those found in normal individuals. 
There was a striking and consistent Th2 bias even among the benign T cells in these 
patients, as well as a reduction in the production of Th1 cytokines (Fig. 1). These results 
demonstrate for the first time that a global Th2 bias exists in these patients that leads to 
skewing of the entire T cell repertoire, both benign and malignant, toward enhanced 
production of Th2 cytokines. This overproduction of Th2 cytokines by both malignant and 
benign T cells likely contributes to the pruritus, reduced Th1 responses and the 
susceptibility to infections observed in these patients.  
 The remaining non-clonal benign T cells in patients with L-CTCL would be expected 
to have a variety of cytokine production capacities. Given the known ability of Th2 cells 
to suppress Th1 responses and to force a Th2 bias on other T cells (22, 23),  we 
hypothesized that the malignant T cells may suppress the activity of benign T cells, 
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silencing Th1 responses, as has been suggested previously (24). Indeed, when we 
separated and cultured non-clonal T cells from the blood and skin lesions of patients 
away from the malignant clone, we observed improved Th1 responses (Fig. 2). When we 
co-cultured T cells from healthy individuals with L-CTCL T cells, we saw a marked 
inhibition of Th1 responses (Fig. 3, 4). Incubation of co-cultures with neutralizing 
antibodies to IL-4 and IL-13 restored Th1 responses, suggesting Th2 cytokines 
produced by malignant T cells may be directly responsible for the suppression of Th1 
responses we observed in our patients and in T cells from healthy donors. 
 To study this question in living patients, we evaluated L-CTCL patients treated with a 
variety of modalities that had in common only the reduction in the number of circulating 
malignant T cells. We found that, regardless of the underlying mechanism of action of 
particular therapies, treatments that reduced malignant T cell burden were invariably 
associated with enhanced Th1 responses (Figure 5). Although circumstantial, our results 
suggest that Th2 cytokines produced by malignant T cells play a critical role in 
suppressing Th1 responses in our patients. 
 In summary, we report a marked Th2 bias in both the benign and malignant T cells in 
patients with L-CTCL and we find that Th2 cytokine production by the malignant clone 
likely suppresses Th1 responses in these patients. Th1 responses improved in vitro 
when the benign T cells were cultured away from the malignant clone, when IL-4 and IL-
13 activities were blocked in vitro with neutralizing antibodies, and in patients 
themselves after treatment with therapies that reduced the number of circulating 
malignant T cells. The suppression of Th1 responses in these patients by IL-4 and IL-13 
suggests that neutralization of these cytokines may be beneficial in enhancing immune 
responses. Aeroderm, a recombinant small protein antagonist of the IL-4/IL-13 receptor 
formulated for skin injection, was previously in clinical trials for the treatment of severe 
AD (27). By inhibiting Th2 responses and enhancing Th1 responses, IL-4/IL-13 
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antagonists have the potential to enhance immune responses to both skin pathogens 
and to the malignant T cells themselves. 
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Figure legends 
Fig. 1. Both benign and malignant T cells are strongly Th2-biased in patients with 
L-CTCL.  Clonal malignant T cells were definitively identified by staining with TCR Vβ 
antibodies specific for each patient's malignant clone. The cytokine production of 
malignant (clonal) and benign (non-clonal) T cells was evaluated by stimulating cells with 
PMA and ionomycin, surface staining for CD3, CD4 and the malignant TCR Vβ 
clonotype, then performing intracellular cytokine staining followed by flow cytometry 
analysis. (A) Representative results from patient 330 are shown. Th2 cytokines, 
including IL-4 and IL-13, were produced at high levels by both benign and malignant T 
cells. (B) Th2 cytokine production was elevated and Th1 cytokine production was 
reduced in both the benign (non-clonal) and malignant (clonal) T cells from L-CTCL 
patients as compared to normal controls. 12 healthy individuals and 12 patients with L-
CTCL are shown. Increased IL-4 production and loss of IFNγ and TNFα production were 
observed in both malignant and benign T cells from patients with L-CTCL. The 
production of IL-13 and IL-10 was also elevated in the malignant clones. ** p<0.01, *** 
p<0.001. 
 
Fig. 2. Benign T cells show reduced Th2 and enhanced Th1 responses when 
cultured separately from clonal malignant T cells.  (A, B) Non-clonal benign and 
clonal malignant T cells were isolated from the blood of L-CTCL patients using magnetic 
beads. Clonal and non-clonal T cells were cultured separately with LPS-activated 
autologous DC for 12 days and then assayed for cytokine production by intracellular flow 
cytometry. IFNγ production increased and IL-4 production decreased in non-clonal T 
cells cultured away from the malignant clone but clonal T cells showed no significant 
changes in IFNγ or IL-4 production. Representative dot plots (A) and the mean and SEM 
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of three L-CTCL patients (B) are shown. (C) Changes in the expression of Th1- and Th2-
associated transcription factors parallel observed changes in cytokine production in 
benign and malignant T cells cultured separately. In benign T cells cultured away from 
the malignant clone, expression of GATA-3 (Th2) decreased and expression of t-BET 
(Th1) increased whereas expression levels of both transcription factors remained 
unchanged in malignant T cells. Expression of RORγ (Th17) was low in both cell 
populations both before and after culture. (D) Th1 responses are also enhanced in 
lesional skin T cells cultured away from the malignant clone. T cells were isolated from 
lesional skin, separated into non-clonal and clonal T cells and then cultured separately 
with LPS-activated autologous DC. Non-clonal T cells from lesional skin showed a 
marked enhancement of IFN-γ production after culture away from the malignant clone. 
*p<0.05. 
 
Fig. 3. Soluble factors from L-CTCL T cells suppress Th1 responses of PBMC from 
healthy donors. PBMC from healthy donors were co-cultured with PBMC from L-CTCL 
patients with high malignant T cell burden for 12 days either in direct contact or in a 
transwell system, then assayed for cytokine production by flow cytometry. Production of 
IFN-γ was significantly reduced after culture with L-CTCL PBMC in both direct contact 
and in transwell systems. (A) Representative dot plots and (B) mean and SEM from 3 
independent experiments are shown. ***p<0.001. 
 
Fig. 4. Neutralization of IL-4 and IL-13 restores Th1 responses. PBMC from healthy 
donors were co-cultured with L-CTCL PBMC using a transwell system with or without 
neutralizing antibodies to IL-4 and IL-13 or appropriate isotype controls.  Cytokine 
production was then determined by flow cytometry. Dot plots are gated to show only 
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healthy CD4+ T cells. Representative data from one experiment (A) and cumulative data 
from 3 independent experiments (B) are shown. **p<0.005, ***p<0.001. 
 
Fig. 5. A variety of treatment modalities that reduce tumor burden enhance Th1 
responses of benign T cells in vivo. (A) Clinical photos of patients before and after the 
indicated therapies are shown. (B) All modalities reduced the number of circulating 
malignant T cells (red) and (C) all were associated with decreased production of IL-4 
and increased production of both IFNγ and IL-2 by benign T cells after therapy (after tx).  
 
